TCT-128: Transaortic Transcatheter Aortic Valve Implantation Using the Sapiens Valve for Patients with no Optional Artery Access. A New Promising Approach  by unknown
TUESDAY, NOVEMBER 8, 2011, 10:15 AM - 12:25 PM
Mortality at 30 days and 1 year was 11.8% and 22.7%, respectively. At one year follow-
up, all but one patient was NYHA class 1 or 2 and the mean gradient across the aortic
valve remained stable (14 ± 5 mmHg).
Conclusion: This multicenter study shows that THV-in-THV implantation is feasible
and results in satisfactory short and mid-term outcomes.
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Background: Despite growing interest in transcatheter aortic valve implantation
(TAVI) as an alternative to surgical aortic valve replacement for select patients with
severe aortic stenosis, relatively little is known about the predictors of adverse
outcomes following TAVI.
Methods: We studied 126 consecutive patients (mean age 84±5 years; 59% women;
Euroscore: 21.3±11) with symptomatic severe aortic stenosis (aortic valve area<0.6
cm2/m2 and NYHA class≥III) who underwent TAVI at our institution between
November 2008 and May 2011 using transfemoral Edwards-Sapien© (66%),
transapical Edwards-Sapien© (23%) and transfemoral Medtronic Corevalve© (11%)
devices. The primary end-point was the occurrence of any cardiovascular death (fatal
stroke, MI, heart failure and/or sudden cardiac death). We also recorded the incidence
of major adverse cardiovascular events (MACE), that combined cardiovascular death+
stroke+ myocardial infarction+ acute heart failure.
Results: The acute procedural success rate was 98%; at 1 year, the cumulative
incidence of MACE and cardiovascular death was 31.1% and 9 %, respectively. In
multivariable analyses adjusting for clinical and echocardiographic risk factors
(including left ventricle ejection fraction), presence of a baseline transvalvular gradient
<40 mmHg was a significant predictor of 30-day MACE in the total sample (OR=4.5,
95% CI 1.6-12.4; P=0.004) as well as in patients with an ejection fraction ≥50%
(OR=12.5, 95% CI 3.4-46.2; P<0.001). In multivariable analyses, low transvalvular
gradient was also associated with increased hazards for MACE (HR=3.2, 95% CI 1.6-
6.4; P<0.001) and cardiovascular death (HR=3.9 95% CI 1.1-13.9; P=0.03) within 1
year following TAVI
Conclusion: Presence of a low transvalvular gradient (<40 mmHg) prior to TAVI was
associated with a greater risk of major adverse events, including cardiovascular death,
up to 1 year following the procedure. Pre-procedural transvalvular gradient could be
used to identify patients at a high risk for adverse outcomes following TAVI.
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Background: Access for transcatheter aortic valve implantation (TAVI) in patients
with no optional peripheral artery access still remains a serious issue, since transapical
approach is frequently associated with myocardial damage and pleural effusion.
Recently, Transaortic (TAo) approach has been developed to address these problems.
The purpose of this study was to evaluate the efficacy and safety of TAo approach in
TAVI using the Edwards Sapien valve.
Methods: Among 365 patients included in our prospective TAVI database (October
2006 to June 2011), TAo-TAVI was performed in 25 consecutive patients excluded
from femoral or subclavian access since january 2011. We evaluated the clinical
outcomes according to the VARC definitions. The access was carefully selected
according to CT-scan assessment of ascending aorta. Through an upper
ministernotomy, the aorta was prepared for cannulation and punctured. After retrograde
crossing of the aortic valve, the Ascendra sheath was inserted to deploy the valve after
predilatation.
Results: Patients were 84.9±4.2 (76-93) years old and EuroSCORE 17.1±7.9%. The
23 mm valve was used in 5 cases, 26mm in 15 and 29mm in 5. In 4 patients, complete
off pump revascularization (2-4 grafts) was achieved in the same session before TAVI.
Device success was achieved in all cases. Post-procedural aortic regurgitation ≥2/4
was observed in 1 case (4%). Transfusion ≥4units was required in 1 patient (10%) who
had annulus rupture successfully corrected. There were no access site complications,
no cases of valve migration or conversion to open-heart surgery. Intensive care unit
and total hospital stay were 3.1±2.1 and 19.0±6.8 days, respectively. Mortality and
combined safety endpoint at 30-day was noted in 0 and 10%, respectively.
Conclusion: Transaortic approach for Sapiens XT valve implantation can be performed
with a low complication rate and excellent outcome. This approach may be a promising
alternative to the conventional transapical approach.
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Background: Transcatheter Aortic Valve Implantation (TAVI) favourably compared
to conservative management in inoperable patients and to surgery in high-risk patients
affected by aortic stenosis. However, the outcome of high-risk and inoperable patients
resulting ineligible for TAVI has not been yet investigated. We prospectively evaluated
clinical outcome of patients affected by aortic valve stenosis ineligible for TAVI.
Methods: All high surgical risk patients referred to our cardiovascular department for
severe aortic stenosis requiring valve replacement were included in a prospective
single-centre registry. High surgical risk was defined by the presence of: 1.age ≥ 75
with a logistic EuroSCORE ≥ 15%; or 2.age > 65 plus one or more inoperable criteria
such as porcelain aorta, previous open chest surgery, neurological dysfunction, severe
chronic obstructive pulmonary disease (FEV1 < 1L), liver cirrhosis (Child ≥B), severe
chronic kidney disease, stroke, severe connective tissue disease or hostile thorax.
Eligibility criteria for TAVI were based on clinical and anatomic characteristics
compatible with the current devices: Medtronic CoreValve III generation and Edwards
Sapien/Sapien XT transfemoral or transapical approach.
Results: Of 300 patients who were denied surgery, 225 (75%) resulted eligible for
TAVI and 75 (25%) did not. Causes of ineligibility for TAVI were frailty status (n=22),
severe mitral regurgitation (≥ 3+/4) (n=18), inadequate aortic annulus size (n=18),
severe left ventricular dysfunction (n=6), no-access (n=8) and hemorrhagic diathesis
(n=3). Of the 225 eligible for TAVI, 187 (83%) underwent TAVI with a 30-day
mortality of 4.2%; 18 (8%) died before intervention; 16 (7%) refused the procedure; 4
(2%) were excluded by referral physician and died. At 1-year, estimated survival was
89% in TAVI patients versus 49% in patients ineligible to TAVI. Indeed, cardiovascular
mortality was largely prevalent in TAVI ineligible patients, whereas non-cardiovascular
mortality was largely prevalent in TAVI patients.
Conclusion: Using current devices and approaches the most frequent causes for TAVI
ineligibility are not related to anatomical criteria but to clinical conditions. Patients
not eligible for TAVI have very high risk clinical features and very poor outcome.
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Background: SAVR is an invasive intervention, carrying a risk of perioperative
mortality and an alternative treatment option, transcatheter aortic valve implantation
(TAVI), has been developed. The clinical efficacy of TAVI was demonstrated in a
recently published randomized controlled trial (PARTNER). To date, however, there
is little information about the cost-effectiveness of TAVI relative to SAVR.
Methods: A 20 year Markov model was developed in Microsoft Excel® from the
perspective of the UK NHS. Treatment options included were TAVI and SAVR.
Treatment specific mortality and adverse event data were taken from the PARTNER
study (Cohort A) which was supplemented by UK specific life table information.
Resource use and cost data were drawn, where possible, on information from publicly
available national databases. Other parameters were taken from published literature.
Decrements were applied to age-specific EQ-5D population norms to generate Quality
Adjusted Life Years (QALYs). Alternative modelling approaches and data sources for
key parameters were included into the model. Extensive probabilistic and deterministic
sensitivity analyses were performed. Costs and benefits were discounted at an annual
rate of 3.5%
Results: The base case Incremental Cost-Effectiveness Ratio (ICER) was £30,538 per
QALY gained (95% Crl £21,322 to £39,287). At willingness to pay thresholds of
£30,000 per QALY, the probability that TAVI is cost-effective is 44%. Results were
not sensitive to changes in baseline survival curve, approach used to model the benefit
of TAVI, or procedure time, but sensitive to changes in procedure cost and resource
use.
Conclusion: TAVI may be a cost-effective alternative to conventional surgery at a
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